Description

Delcasertib (KAI-9803) hydrochloride is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) hydrochloride could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI)[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–COVID-19-immunoregulation–C120H200ClN45O34S2—-[1]Miyaji Y, et al. Distribution of KAI-9803, a novel δ-protein kinase C inhibitor, after intravenous administration to rats. Drug Metab Dispos. 2011 Oct;39(10):1946-53.|[2]Bates E, et al. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation. 2008 Feb 19;117(7):886-96.—-2916.74–99.86–OC(C=C1)=CC=C1C[C@H](NC([C@H](CO)NC([C@H](CC(N)=O)NC([C@@H](NC([C@H](CO)NC([C@@H](N)CSSC[C@H](N)C(N[C@H](C(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(O)=O)CCCNC(N)=N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC2=CC=C(C=C2)O)=O)=O)=O)CC3=CC=CC=C3)=O)=O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(C)C)C(NCC(N[C@H](CO)C(N[C@@H](C(O)=O)CC(C)C)=O)=O)=O)=O)=O.[H]Cl–Inflammation/Immunology; Cardiovascular Disease–H2O : 100 mg/mL (ultrasonic)–PKC–PKCδ–Epigenetics;TGF-beta/Smad–Peptides